AstraZeneca's COVID-19 Vaccine On Hold: A Reminder Product Development Is Never Straightforward
Phase III Trial Stopped A Week After Initiation
AstraZeneca – one of the frontrunners in the race to develop a COVID-19 vaccine – has voluntarily put a hold on the Phase III trial due to an adverse event.
You may also be interested in...
US FDA officials fear comparator arms would be unwieldy for ongoing trials as they consider alternative methods to measure efficacy if placebo controls can't be maintained for the studies of other candidate vaccines once a product is on the market.
US lawmakers press the Surgeon General and NIH Director on how to instill vaccine confidence in an increasingly wary American public.
The move reduces the pressure on the companies to rush development, but also relieves burden on the FDA to approve a candidate too soon.